Ebrotidina: nuevo antagonista H2

Padrón Pérez, Noel; Fernández Vallín-Cárdenas, Eulalia.
Rev. cuba. med. gen. integr ; 15(4): 436-8, 1999.
Artículo en Español | CUMED | ID: cum-18014

Documentos relacionados

  1. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding.
  2. Major Shifts in Acid Suppression Drug Utilization After the 2019 Ranitidine Recalls in Canada and United States.
  3. Development and in vitro/in vivo evaluation of famotidine hydrochloride bioadhesive sustained release suspension.
  4. Effect of proton pump inhibitors and H2 antagonists on gastric wall uptake in myocardial perfusion scan with 99mTc-sestamibi.
  5. H<sub>2</sub> antagonists, proton pump inhibitors and COVID-19.
  6. No need for H<sub>2</sub>-antagonists in premedication regimens for paclitaxel infusions: less is more.
  7. Reducing the effect of proton pump inhibitors augmenting gastrointestinal sestamibi uptake.
  8. Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro.
  9. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect.
  10. Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19.